Amneal Pharmaceuticals announced that the US Court of Appeals for the Federal Circuit has upheld a March 2017 ruling finding that Lannett infringed on US patents 6,750,237 and 7,220,767, which are related to Zomig zolmitriptan nasal spray.
Amneal President and CEO Rob Stewart said, “We are pleased with the Federal Circuit’s affirmance of the District Court Decision. We look forward to continuing to supply this product to patients and will continue to actively protect our intellectual property.”
Read the Amneal Pharmaceuticals press release.
